Affibody-Conjugated Hydrogels for Controlled BMP-2 Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Uncontrolled release of bone morphogenetic protein-2 (BMP-2) from current delivery vehicles leads to off-target bone growth and adverse effects, necessitating improved control over BMP-2 delivery to enhance efficacy and reduce side effects in bone regeneration therapies.
Innovation Solution
Development of hydrogels incorporating BMP-2-specific affibodies with varying affinities, which are integrated into polyethylene glycol-maleimide hydrogels to control the release of BMP-2, utilizing affibodies with distinct dissociation constants to modulate protein delivery and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BMP-2 is delivered using absorbable collagen sponge relying on weak electrostatic interactions, then the delivery vehicle is simple and easy to manufacture, but the ability to retain BMP-2 is limited leading to uncontrolled release
Solution Approach 1:
The patent introduces affibodies as intermediary molecules that mediate between the delivery vehicle and BMP-2. These affibodies specifically bind to BMP-2 with high affinity, acting as a bridge that enhances retention without requiring direct complex conjugation of BMP-2 to the delivery vehicle matrix.
Solution Approach 2:
The patent changes the binding parameter from weak electrostatic interactions to high-affinity specific binding by incorporating affibodies. This parameter change in interaction strength dramatically improves BMP-2 retention capability while maintaining delivery vehicle integrity.
2Reliability
If BMP-2 is delivered using affinity-mediated interactions with heparin, then sustained protein delivery is achieved, but heparin interacts with numerous other proteins making behavior unpredictable in complex in vivo environments
Solution Approach 1:
The patent applies local quality by designing affibodies with highly specific binding sites that recognize only BMP-2. This localized specificity at the molecular binding interface ensures that the delivery system interacts only with the intended target protein, eliminating off-target interactions that plague heparin-based systems.
Solution Approach 2:
Affibodies serve as specialized intermediary molecules that provide selective mediation between the delivery vehicle and BMP-2. Unlike heparin's broad interactions, affibodies are engineered to mediate specifically with BMP-2 through their unique binding pockets, ensuring predictable behavior in complex biological environments.
3Duration of action of moving object
If chemical conjugation of BMP-2 to delivery vehicle is used, then burst release is reduced and protein presentation is prolonged, but protein-receptor binding is interfered with altering biological function
Solution Approach 1:
The patent segments the delivery system into three functional components: the delivery vehicle matrix, the affibody binding molecules, and the BMP-2 therapeutic protein. This segmentation allows each component to perform its function independently - the affibodies control retention while leaving BMP-2's biological function intact.
Solution Approach 2:
Affibodies act as intermediary binding molecules that temporarily hold BMP-2 without interfering with its biological activity. The reversible nature of affibody-BMP-2 interactions allows BMP-2 to be released in an active conformation, maintaining its ability to bind receptors and exert therapeutic effects.
4Reliability
If affibodies with high affinity for BMP-2 are used, then BMP-2 retention is improved, but the release control precision may be reduced due to very slow dissociation
Solution Approach 1:
The patent applies dynamics by using affibodies with reversible binding characteristics. The binding is dynamic rather than permanent, allowing BMP-2 to associate and dissociate from the delivery vehicle in response to local concentration gradients and biological conditions, enabling natural release control.
Solution Approach 2:
By carefully selecting affibodies with specific affinity parameters (Kd values in the nanomolar range), the patent optimizes the balance between retention and release. The parameter choice ensures sufficiently strong binding for retention while maintaining dissociation rates that allow physiological release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The affibody-conjugated hydrogels provide controlled release of BMP-2, reducing off-target effects and prolonging the activity of BMP-2, thereby improving bone regeneration outcomes by ensuring precise spatiotemporal protein delivery.
Implementation Method 1
Affinity-mediated protein release relies primarily on the equilibrium dissociation constant (KD) between the protein and material to control the rate of protein release
Implementation Method 2
Hydrogels containing affibodies and uses thereof
Data Source
AI summary
Provided are unique affibodies specific for bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), inteleukin-4 (IL-4), and glial derived neurotrophic factor (GDNF), and well as hydrogels that include the affibodies and the corresponding protein. Also provided are methods of using the hydrogels, for example to treat bone injury, wounds, and neuron injury. In some examples, the hydrogel includes at least two different affibodies specific for the same protein, but have different disassociation constants (KD).